



iPSC expansion and differentiation: current landscapes and future development


What area are you working in?



What type of transplantation are your projects aimed at?




What starting cells do you use?



At what stage(s) of the translational cell therapy workflow are your current research projects?




What cells are you generating from your iPSCs?




What method do you use to differentiate your iPSCs?




Which statement best describes how you feel about using off-the-shelf vs. customized iPSCs?




What process parameters are important for you?



Which platform/system do you use for your iPSC cultivation?



How do you validate iPSC differentiation?




How do you control differentiation?




What expansion conditions do you use?



Over what timeframe does your expansion take place? (%)



Over what timeframe does your differentiation take place? (%)




Which statement about GMP most applies to you?




What are the biggest challenges in iPSC differentiation and expansion?



What is the future for GMP-grade iPSC lines? "an increasingly crowded market"



Should companies invest in generating their own lines, or is there an opportunity for a centralized repository of iPSC lines?



About the respondents

